Features of antiplatelet therapy for cerebrovascular diseases in elderly patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Ischemic stroke and other diseases of the cardiovascular system associated with atherosclerosis occupy a leading place among the causes of death and permanent disability in older age groups. One of the most effective ways to prevent cardiovascular diseases is antiplatelet therapy. The article discusses the features of antiplatelet therapy in elderly patients. Based on the results of modern studies, new scientific publications and clinical recommendations, data on the efficacy and safety of platelet antiplatelet agents of various pharmacological groups with long-term use in patients of older age groups are summarized.

About the authors

E. A. Shirokov

Branch of the S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation

Author for correspondence.
Email: Evg-747747@yandex.ru

профессор

Russian Federation, Moscow

V. L. Glotko

Branch of the S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation; The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation

Email: Evg-747747@yandex.ru

доцент, полковник медицинской службы запаса

Russian Federation, Moscow; Moscow

O. M. Levin

National Medical Research Center for High Medical Technologies – the A.A.Vishnevsky Central Military Clinical Hospital Ministry of Defense of the Russian Federation

Email: Evg-747747@yandex.ru
Russian Federation, Krasnogorsk, Moscow Region

References

  1. Бурячковская Л.И., Ломакин Н.В., Сумароков А.Б., Доценко Ю.В. Значение особенностей действия антиагрегантов для выбора терапии сосудистого больного // Тромбоз, гемостаз и реология. – 2017. – № 4 (72). – С. 6–13. doi: 10.25555/THR.2017.4.0803
  2. Здравоохранение в России. 2019: Стат. сб. / Росстат. – М., 2019. – 170 с.
  3. Клинические рекомендации по ведению больных с ишемическим инсультом и транзиторными ишемическими атаками / Под ред. Л.В.Стаховской. – М., 2017. – 208 с.
  4. Ломакин Н.В., Сумароков А.Б., Доценко Ю.В. и др. Индивидуальный подход к применению антитромбоцитарной терапии. На что опереться в решении? // Атеротромбоз. – 2017. – № 2. – С. 70–78. doi: 10.21518/2307-1109-2017-2-70-78
  5. Мачинский П.А., Плотникова Н.А., Ульянкин В.Е. и др. Сравнительная характеристика показателей заболеваемости ишемическим и геморрагическим инсультом в России // Мед. науки. Патологическая анатомия. – 2019. – № 2 (50). – С. 112–131. doi: 10.21685/2072-3032-2019-2-11
  6. Сумароков А.Б., Широков Е.А., Бурячковская Л.И. Антитромбоцитарная терапия в профилактике ишемического некардиоэмболического инсульта. Основные положения современных рекомендаций. – М., 2015. – 34 с.
  7. Суслина З.А., Танашян М.М., Домашенко М.А. Индивидуализация антиагрегантной терапии у пациентов с цереброваскулярными заболеваниями // Клин. фармакол. тер. – 2011. – № 5. – С. 70–74.
  8. Широков Е.А., Симоненко В.Б., Овчинников Ю.В. Транзиторные ишемические атаки и малые инсульты: современные терапевтические стратегии // Леч. врач. – 2020. – № 5. – С. 7–11. doi: 10.26295/OS.2020.56.70.001
  9. Balint A., Tornyos D., Alaoui O. et al. Network Meta-Analis of Ticagrelor for Stroke prevention in patients at High Risk for Cardiovascular or Cerebrovascular Events // Stroke. – 2021. – Vol. 52, N 9. – P. 2809–2816. doi: 10.1161/STROKEAHA.120.032670
  10. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) // Lancet. – 1996. – Vol. 348, Iss. 9038. – P. 1329–1339. doi: 10.1016/s0140-6736(96)09457-3
  11. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in highrisk patients // BMJ. – 2002. – Vol. 324, N 71. – P. 71–86. DOI: org/10.1136/bmj.324.7329.71
  12. Chen Z.M., Sandercock P., Pan H.C. et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups // Stroke. – 2000. – Vol. 31, N 6. – P. 1240–1249. doi: 10.1161/01.str.31.6.1240
  13. Cho Y.J., Koo J.S., Park J.M. et al. Factors associated with stroke progression in acute cerebral infarction // Int. J. Stroke. – 2008. – Vol. 3. – P. 405–409.
  14. Diener H.C., Sacco R., Yusuf S. Steering Committee. PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS) // Cerebrovasc. Dis. – 2007. – Vol. 23, N 5–6. – P. 368–380. doi: 10.1159/000100105
  15. Greving J.P., Diener H., Reitsma J.B. et al. Antiplatelet Therapy After Noncardioembolic Stroke // Stroke. – 2019. – Vol. 50, N 7. – P. 1812–1818. doi: 10.1161/STROKEAHA.118.024497.
  16. Johnston S.C., Amarenco P., Denison H. et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA // N. Engl. J. Med. – 2020. – Vol. 383, N 3. – P. 207–217. doi: 10.1056/NEJMoa1916870
  17. Kennedy J., Hill M.D., Ryckborst K.J. et al. For the FASTER investigators: Fast Assessment of Stroke and Transient Ischemic Attack to prevent Early Recurrence (FASTER): a randomized controlled pilot trial // Lancet Neurol. – 2007. – Vol. 6, N 11. – P. 961–969. doi: 10.1016/S1474-4422(07)70250-8
  18. Li Z., Wang Y., Zhao X. et al. Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack // J. Am. Heart Assoc. – 2016. – Vol. 5, N 3. – P. e003038. DOI: 10/1161/JAHA.115.003038
  19. Linxin Li, Catherine A Scott, Peter M. Rothwell. Oxford Vascular Study. Trends in Stroke Incidence in High-Income Countries in the 21st Century Population-Based Study and Systematic Review // Stroke. – 2020. – Vol. 51, N 5. – P. 1372–1380. doi: 10.1161/STROKEAHA. 119.028484
  20. McHutchison C., Blair G.W., Appleton J.P. et al. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis // Stroke. – 2020. – Vol. 51, N 8. – P. 2374–2385. doi: 10.1161/STROKEAHA. 120.029454
  21. Niu P.-P., Guo Z.-N., Jin H. et al. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis // BMJ Open. – 2016. – Vol. 6, N 3. – P. e009013. doi: 10.1136/bmjopen-2015-009013.
  22. Rothwell P., Algra A., Chen Z. et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials // Lancet. – 2016. – Vol. 388, Iss. 10042. – P. 365–375. doi: 10.1016/S0140-6736(16)30468-8
  23. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe // Europ. Heart J. – 2021. – Vol. 42, Iss. 25. – P. 2439–2454. doi: 10.1093/eurheart/ehab309
  24. Shaban A., Monlezun D.J., Rincon N. et al. Safety and Efficacy of Acute Clopidogrel Load in Patients with Moderate and Severe Ischemic Strokes // Stroke Research and Treatment. – 2016. – Vol. 2016, Art. 8915764. DOI: 10/1155/2016/8915764
  25. Uchiyama S., Amarenco P., Minematsu K., Wong K.S.L. TIA as acute Сerebrovascular Syndrome // Front. Neurol. Neurosci. – 2014. – Vol. 33. – P. 135–146. doi: 10.1159/isbn.978-3-318-02459-3
  26. Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice // Europ. Heart J. – 2021. – Vol. 42, Iss. 34. – P.3227–3337. doi: 10.1093/eurheartj/ehab484
  27. Wang Y., Meng A., Wang A. et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of Function Carries with Stroke or TIA // N. Engl. J. Med. – 2021. – Vol 385 (27). – P. 2520–2530. DOI: 10/1056/NEJMoa2111749
  28. Zurru M., Orzuza G. Epidemiological Aspects of Stroke in Very Old Patients// Cardiovascular and Haematological Disorders-Drug Targets. – 2011. – Vol. 11, N 1. – P. 2–5. doi: 10.2174/187152911795945187

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Shirokov E.A., Glotko V.L., Levin O.M.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 01975 от 30.12.1992.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies